

ARG59356 anti-AGO2 / Argonaute 2 antibody

Package: 100 μl Store at: -20°C

Summary

Product Description	Rabbit Polyclonal antibody recognizes AGO2 / Argonaute 2
Tested Reactivity	Hu, Ms, Rat
Tested Application	FACS, ICC, IP, WB
Host	Rabbit
Clonality	Polyclonal
Isotype	lgG
Target Name	AGO2 / Argonaute 2
Species	Human
Immunogen	Synthetic peptide derived from Human AGO2 / Argonaute 2.
Conjugation	Un-conjugated
Alternate Names	EC 3.1.26.n2; eIF2C 2; PPD; Protein slicer; Argonaute RISC catalytic component 2; EIF2C2; Argonaute2; PAZ Piwi domain protein; Q10; hAgo2; Protein argonaute-2; Eukaryotic translation initiation factor 2C 2; eIF-2C 2

Application Instructions

Application table	Application	Dilution
	FACS	1:50
	ICC	1:50 - 1:200
	IP	1:50
	WB	1:500 - 1:2000
Application Note	* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.	
Positive Control	HeLa	
Observed Size	~ 96 kDa	


Properties

Form	Liquid
Purification	Affinity purified.
Buffer	PBS (pH 7.4), 0.02% Sodium azide and 50% Glycerol.
Preservative	0.02% Sodium azide
Stabilizer	50% Glycerol

Bioinformation

Gene Symbol	AGO2
Gene Full Name	argonaute RISC catalytic component 2
Background	This gene encodes a member of the Argonaute family of proteins which play a role in RNA interference. The encoded protein is highly basic, and contains a PAZ domain and a PIWI domain. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]
Function	Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs direct RISC to complementary mRNAs that are targets for RISC-mediated gene silencing. The precise mechanism of gene silencing depends on the degree of complementarity between the miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA generally results in silencing due to endonucleolytic cleavage of the mRNA specifically by AGO2. Binding of RISC to a partially complementary mRNA results in silencing through inhibition of translation, and this is independent of endonuclease activity. May inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. May also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. The inhibition of translational initiation leads to the accumulation of the affected mRNA in cytoplasmic processing bodies (P-bodies), where mRNA degradation may subsequently occur. In some cases RISC- mediated translational repression is also observed for miRNAs that perfectly match the 3' untranslated region (3'-UTR). Can also up-regulate the translation of specific mRNAs under certain growth conditions. Binds to the AU element of the 3'-UTR of the TNF (TNF-alpha) mRNA and up-regulates translation under conditions of serum starvation. Also required for transcriptional gene silencing (TGS), in which short RNAs known as antigene RNAs or agRNAs direct the transcriptional repression of complementary promoter regions. [UniProt]
Calculated Mw	97 kDa
PTM	Hydroxylated. 4-hydroxylation appears to enhance protein stability but is not required for miRNA- binding or endonuclease activity. [UniProt]
Cellular Localization	Cytoplasm, P-body. Nucleus. Note=Translational repression of mRNAs results in their recruitment to P- bodies. Translocation to the nucleus requires IMP8. [UniProt]

Images



ARG59356 anti-AGO2 / Argonaute 2 antibody WB image

Western blot: HeLa cell lysate stained with ARG59356 anti-AGO2 / Argonaute 2 antibody.